Drug Trial Radar · NCT06989788
A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
May 6, 2025
Primary completion
Aug 10, 2026
Study completion Aug 10, 2026
Sponsor
- Lead sponsor
- AstriVax TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of repeated administrations of AVX70371 in healthy participants.
Conditions
- Chronic Hepatitis b
Interventions
AVX70371Biological
AstriVax Therapeutics' HBV immunotherapeutic
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of solicited adverse eventsTime frame: During a 14-day follow-up period after each administration
- Occurrence of unsolicited adverse eventsTime frame: From Day 1 up to 1 month after the last administration
- Occurrence of hematological and biochemical laboratory abnormalitiesTime frame: From Day 1 up to 1 month after the last administration
- Occurrence of adverse events of special interestTime frame: From Day 1 up to 1 year after the last administration
- Occurrence of serious adverse eventsTime frame: From Day 1 up to 1 year after the last administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC)
Ghent, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.